Use of newer-generation drug-releasing stent results in lower rate of adverse cardiac events
Compared with a bare-metal stent, the use of a stent with a biodegradable polymer that releases the drug biolimus resulted in a lower rate of major adverse cardiac events at 1 year among patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack) undergoing primary percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the August 22/29 issue of JAMA.
"The efficacy and safety of drug-eluting [releasing] stents compared with bare-metal stents remains controversial in patients with STEMI undergoing primary PCI," according to background information in the article. "Early generation drug-eluting stents releasing sirolimus or paclitaxel from durable polymers reduce the need for repeat revascularization compared with bare-metal stents. However, vessel healing is delayed with evidence of chronic inflammation related at least in part to the persistence of durable polymer components in patients with acute STEMI. Newer-generation drug-eluting stents with biodegradable polymers provide controlled drug release with subsequent degradation of the polymer rendering the stent surface more closely to a bare-metal stent after the period of biodegradation."
Lorenz Räber, M.D., of Bern University Hospital, Bern, Switzerland, and colleagues compared the efficacy and safety of stents eluting biolimus from a biodegradable polymer with bare-metal stents of otherwise identical design. The randomized controlled trial included 1,161 patients with STEMI at 11 sites in Europe and Israel between September 2009 and January 2011. Clinical follow-up was performed at 1 and 12 months. Patients were randomized to receive the biolimus-eluting stent (n = 575) or the bare-metal stent (n = 582). The primary outcome measured for the study was the rate of major adverse cardiac events, a composite of cardiac death, target vessel-related reinfarction, and ischemia-driven target-lesion revascularization at 1 year. The average age of patients was 61 years and 79 percent were men.
The researchers found that at one year, the primary end point of major adverse cardiac events occurred in 4.3 percent of patients receiving biolimus-eluting stents and 8.7 percent of patients receiving bare-metal stents, which is a significant 4.4 percent absolute reduction and 51 percent relative reduction in the risk of major adverse cardiac events (and the prevention of 42 events per 1,000 patients treated with biolimus-eluting stents compared with bare-metal stents at 1 year). "For cardiac death alone, the percentages were smaller [(2.9 percent vs. 3.5 percent, respectively]. The treatment effect in favor of patients receiving biolimus-eluting stents was attributable to both a lower risk of target vessel-related reinfarction (0.5 percent vs. 2.7 percent) and ischemia-driven target-lesion revascularization (1.6 percent vs. 5.7 percent)." At 1 year, rates of definite stent thrombosis amounted to 0.9 percent among patients receiving biolimus-eluting stents and 2.1 percent among patients receiving bare-metal stents.
The authors also observed no differences in all-cause and cardiac mortality between the groups at 1 year. "In addition to the device-oriented primary outcome measure, we recorded a lower risk of the comprehensive patient-oriented composite of death, any reinfarction, and any revascularization in favor of biolimus-eluting stents (8.4 percent vs. 12.2 percent)."
" our results suggest better clinical outcomes in terms of major adverse cardiac events of a stent releasing biolimus from a biodegradable polymer compared with a bare-metal stent for the treatment of patients with STEMI."
In an accompanying editorial, Salvatore Cassese, M.D., and Adnan Kastrati, M.D., of the Technische Universitat, Munich, Germany, write that the findings from this study (COMFORTABLE AMI) and from a series of previous trials on drug-eluting stents (DESs) in patients with heart attack provide several important lessons.
"First, the efficacy of DESs vs. bare-metal stents (BMSs) in STEMI is already established and, therefore, further studies comparing these interventions might not be needed. Second, concerns about a possible very late safety issue with DESs are apparently DES-type specific, mostly related to first-generation DESs and less justified with newer DESs. Larger randomized trials with longer follow-up and head-to-head comparisons of the available DES technologies are, however, required to completely eliminate these concerns. These studies should also take broader advantage of intravascular imaging technologies to provide mechanistic insights into the clinical findings. Third, although there is almost no rationale for performing DES vs. BMS studies anymore, it might be conceivable to expect studies that test the hypothesis of noninferiority of new, improved BMSs to available DESs. Until then, recent studies such as the COMFORTABLE AMI trial should make cardiologists feel more comfortable with the use of new-generation DESs in patients with STEMI."
More information: JAMA. 2012;308:777-787.
Journal reference: Journal of the American Medical Association
Provided by JAMA and Archives Journals
- Drug-Eluting stents offer no advantage for A-Fib patients Jun 22, 2012 | not rated yet | 0
- Drug-Eluting stents reduce risk of thrombosis Mar 23, 2012 | not rated yet | 0
- Drug-releasing stents linked with decrease in procedures to unblock coronary arteries Jun 25, 2008 | not rated yet | 0
- Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent Aug 30, 2011 | not rated yet | 0
- Good long-term outcomes for drug-eluting stents Apr 04, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Calculating on-axis elements of a solenoid
5 hours ago I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
latitude & longitude & air pressure
7 hours ago Hi there, I have a peculiar question. Imagine that you are in a earth position, obtained by google, that gives you the latitude and longitude....
Differences of Classical Mechanics when learned with Calc vs algebra?
10 hours ago what are the differences? Every example I find usually has a derivative or integral or some kind of calculus defined concept that seems to make it...
what is the distance traveled
14 hours ago A rough sketch of experiment. Image: http://i43.tinypic.com/14t4sk5.png the red dots represent a side view of path traveled, F is downward force...
Image of a Convex Lens Cut in Half Horizontally
18 hours ago Hello everyone, A friend of mine came up with this question in class and I really do not have a good answer. Suppose you have a convex lens...
Ray tracing through optical system of thick lenses
18 hours ago Can you advise me a free software that allow to draw rays passed throught system of thick lenses (preferable in 3D)?
- More from Physics Forums - Classical Physics
More news stories
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology 15 hours ago | not rated yet | 0
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology 17 hours ago | not rated yet | 0
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology 17 hours ago | not rated yet | 0
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...
Cardiology 17 hours ago | not rated yet | 0
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology May 21, 2013 | 5 / 5 (1) | 0
Existing research shows that bicyclists who wear helmets have an 88 percent lower risk of brain injury, but researchers at Boston Children's Hospital found that simply having bicycle helmet laws in place showed a 20 percent ...
3 hours ago | not rated yet | 0
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
14 hours ago | 4.9 / 5 (7) | 0 |
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
14 hours ago | 4.7 / 5 (3) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
11 hours ago | 5 / 5 (2) | 2 |
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
10 hours ago | 4 / 5 (2) | 0 |
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
11 hours ago | not rated yet | 0 |